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In this report, we have tested the hypothesis that brain-derived
neurotrophic factor (BDNF) is an anterograde neurotrophic fac-
tor in the CNS and have focused on central noradrenergic
neurons that synthesize BDNF. Double-label immunocyto-
chemistry for BDNF and dopamine-b-hydroxylase (DBH), a
marker for noradrenergic neurons, demonstrated that BDNF is
partially localized to noradrenergic nerve fibers and terminals in
the adult rat brain. To test the functional importance of this
anterograde BDNF, we analyzed transgenic mice carrying a
DBH–BDNF minigene. Increased synthesis of BDNF in norad-
renergic neurons of DBH–BDNF mice caused elevated TrkB
tyrosine kinase activation throughout postnatal life in the neo-
cortex, a noradrenergic target region. This afferently regulated
increase in TrkB receptor activity led to long-lasting alterations
in cortical morphology. To determine whether noradrenergic
neuron-expressed BDNF also anterogradely regulated neuronal
survival, we examined a second noradrenergic target, neonatal
facial motoneurons. One week after axotomy, 72% of facial
motoneurons were lost in control animals, whereas only 30–
35% were lost in DBH–BDNF transgenic mice. Altogether,
these results indicate that BDNF is anterogradely transported to
fibers and terminals of noradrenergic neurons, that antero-
gradely secreted BDNF causes activation of TrkB in target
regions, and that this secretion has functional consequences
for target neuron survival and differentiation. This presynaptic
secretion of BDNF may provide a cellular mechanism for mod-
ulating neural circuitry, in either the developing or mature ner-
vous system.
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The neurotrophic factor hypothesis postulates that trophic factors
produced and released by target neurons regulate the survival
and differentiation of their innervating neurons (for review, see
Oppenheim, 1991). Developing neurons, however, may be equally
dependent for survival and differentiation on afferent neuronal
input (for review, see Linden, 1994). For example, deafferenta-
tion can increase the number of neurons lost during the period of
naturally occurring cell death (Sohol and Narayahan, 1975;
Clarke, 1985; Furber et al., 1987; Linden and Pinon, 1987), and
hyperinnervation can increase the survival of target neurons
(Cunningham et al., 1979). These findings suggest the existence
of anterogradely released trophic factors that are functionally
similar to retrogradely acting growth factors such as nerve growth
factor (for review, see Levi-Montalcini, 1987).
One neuronal population that may play an afferent trophic role
during development is brainstem noradrenergic neurons, which
innervate a large number of CNS structures, including the cere-
bral cortex (Jones and Moore, 1977; for review, see Foote et al.,
1983). These central noradrenergic neurons are born from em-
bryonic day (E) 10 to E13 (Lauder and Bloom, 1974), and they
project axons into targets such as the neocortex while cortical
neurons are still undergoing birth, migration, and differentiation
(Altman and Bayer, 1990; Bayer and Altman, 1990). A trophic
role for these early afferents is supported by lesion studies that
demonstrate that the loss of noradrenergic afferents during de-
velopment alters both the number and morphology of cortical
neurons (Maeda et al., 1974; Felten et al., 1982).
The nature of the signal responsible for the trophic effects of
noradrenergic afferents is still unknown. However, locus coer-
uleus neurons make brain-derived neurotrophic factor (BDNF)
(Castren et al., 1995; Conner et al., 1997), a member of the
neurotrophin family (Barde et al., 1982; Leibrock et al., 1989)
known to have effects on many CNS populations, including the
developing cortex (Ghosh et al., 1994; Nawa et al., 1994; Cabelli
et al., 1995; McAllister et al., 1995, 1996). Moreover, recent
evidence indicates that neurotrophins, including BDNF, can be
anterogradely transported in neurons. Specifically, (1) exogenous
neurotrophins can be anterogradely transported in the developing
chick CNS (von Bartheld et al., 1996); (2) BDNF is present in
axons and potentially in terminals of peripheral (Zhou and Rush,
1996; Michael et al., 1997), and central neurons (Fawcett et al.,
1997; Conner et al., 1997); (3) BDNF is localized to vesicles in
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presynaptic terminals (Fawcett et al.,1997) in the CNS; and (4)
neurotrophins can be synthesized and released in an activity-
dependent manner (for review, see Thoenen, 1995). Finally, TrkB
tyrosine kinase receptors have recently been localized to neuro-
nal dendrites in both the hippocampus and cortex (Fryer et al.,
1996; Yan et al., 1997a).
On the basis of these recent findings, we hypothesized that
BDNF may be a trophic signal derived from noradrenergic affer-
ents. In this paper, we have tested this hypothesis and demon-
strate that BDNF is localized to axons and terminals of norad-
renergic neurons, that increased BDNF secretion within the
cortex from noradrenergic afferents can lead to long-lasting
changes in cortical organization, and that increased secretion of
BDNF onto developing target neurons can modify neuronal
survival itself.
MATERIALS AND METHODS
Animals and surgical procedures. The DBH–BDNF mice used in
these studies, lines D481 and D498, have been described previ-
ously (Causing et al., 1997), and were bred and genotyped as
described. As controls for these transgenic mice, we used either
littermates or animals of the same genetic background that were
null for the DBH–BDNF transgene. Mice heterozygous for a
targeted mutation in the BDNF gene (Ernfors et al., 1994) were
obtained from Jackson Laboratory (Bar Harbor, ME) and main-
tained, bred, and genotyped as described previously (Causing et
al., 1997).
For the TrkB and BDNF biochemical analysis, adult or 1 week
old DBH–BDNF, BDNF1/2, or appropriate wild-type controls
were decapitated. For immunocytochemistry, animals were killed
with sodium pentobarbital (65 mg/kg) and then transcardially
perfused with 4% paraformaldehyde or 4% paraformaldehyde/
15% picric acid in phosphate buffer (PB), pH 7.4. Brains were
then removed and post-fixed in 4% paraformaldehyde or 4%
paraformaldehyde/15% picric acid in PB for 30 min at 4°C and
subsequently cleared of picric acid with PBS, pH 7.4. Alterna-
tively, rats were transcardially perfused with 37°C heparinized
PBS followed by 2% paraformaldehyde in 0.1 M PB, pH 7.3, and
were then post-fixed for 2 hr at 4°C. All sections were cryopro-
tected in graded sucrose solutions and sectioned on the cryostat
before immunocytochemical analysis.
For the facial motoneuron studies, postnatal day 5 wild-type or
transgenic animals were anesthetized by inhalation with metofane
to affect. Alternatively, adult female BDNF heterozygote mice
ranging in age from 2.5 to 3 months were anesthetized using
sodium pentobarbital (35 mg/kg). After complete anesthetization
(in accordance with an animal care protocol meeting the stan-
dards of the Canadian Council on Animal Care), the facial nerve
was transected unilaterally at the stylomastoid foramen. One
week after nerve transection, young or adult animals were per-
fused with PBS, pH 7.4, and 4% paraformaldehyde in 0.1 M
NaH2PO4, after which the brains were removed and post-fixed
overnight in the same fixative at 4°C. Brains were then cryopro-
tected overnight in 30% sucrose and sectioned on a cryostat.
Histological and morphometric analysis. For morphometric
analysis of the neocortex, 16 mm sections were stained using cresyl
violet, and neuronal counts were performed in 528-mm-wide
strips extending from corpus callosum to pia, in two separate
regions of the forebrain.
For the analysis of facial motoneuron size and number, 16 mm
serial coronal sections were collected throughout the extent of the
facial motor nuclei and stained with cresyl violet. For size deter-
mination, neuronal profiles containing a nucleus with a distinct
nucleolus were displayed on a video screen, and the cellular
cross-sectional areas were measured using a computer-based im-
age analysis system (Biocom). For neuronal numbers, all neurons
containing a nucleus in the facial nuclei were counted on every
fifth serial 16 mm section using the same image analysis system,
which prevents double measurements of profiles. The numbers
obtained using this approach are not corrected for split nucleoli.
Results were expressed as mean values 6 SEM and were tested
for significance using the one-tailed Student’s t test.
Antibodies, immunoprecipitations, and Western blot analysis. The
following, previously described antibodies were used for the bio-
chemical studies described here: anti-TrkBin, which specifically
recognizes the intracellular domain of TrkB (Fryer et al., 1996);
anti-TrkBout, which specifically recognizes the extracellular do-
main of full-length and truncated TrkB (Knusel et al., 1994);
anti-panTrk 203, which recognizes the intracellular domain of all
Trk family receptors (Hempstead et al., 1992); anti-BDNF, which
recognizes mature BDNF (Santa Cruz Biotechnology, Santa
Cruz, CA) (Causing et al., 1997; Fawcett et al., 1997); and
antiphosphotyrosine 4G10 (UBI).
For biochemical analysis of TrkB, different regions of 1-week-
old and adult mouse brains were dissected out, homogenized, and
lysed in Tris-buffered saline (TBS) lysis buffer (Knusel et
al.,1994) containing 137 mM NaCl, 20 mM Tris, pH 8.0, 1% (v/v)
NP-40, 10% (v/v) glycerol, 1 mM phenylmethyl sulfonyl fluoride
(PMSF), 10 mg/ml aprotinin, 0.2 mg/ml leupeptin, and 1.5 mM
sodium vanadate. Total Trk protein was immunoprecipitated us-
ing 3 ml of anti-panTrk 203. The immunoprecipitates were col-
lected with Protein A-Sepharose (Pharmacia, Dorval, Que´bec,
Canada) for 1.5 hr at 4°C followed by centrifugation. Immuno-
precipitates were then washed three times with cold lysis buffer,
boiled in sample buffer (2% SDS, 100 mM dithiothreitol, 10%
glycerol, and 0.05% bromophenol blue) for 5 min, and electro-
phoresed on 7.5% SDS-polyacrylamide minigels. After electro-
phoresis, proteins were transferred to 0.2 mm nitrocellulose for 1
hr at 0.5 amps, and the membranes were washed 2 3 10 min in
TBS. For all antibodies except antiphosphotyrosine, for which
membranes were blocked in 2% BSA (Sigma, St. Louis), mem-
branes were blocked in 5% nonfat dry milk in TBS for 1.5 hr.
Membranes were then washed 2 3 10 min in TBS, and the
primary antibodies were used overnight at 4°C at dilutions of
1:10,000 for antiphosphotyrosine 4G10 (UBI), 1:2000 for anti-
panTrk 203, 1:5000 for anti-TrkBout, and 1:2000 for anti-TrkBin.
Secondary antibodies were incubated for 1.5 hr at room temper-
ature and were used at dilutions of 1:10,000 for a goat anti-mouse
horse radish peroxidase (HRP) antibody and 1:10,000 for a goat
anti-rabbit HRP antibody (Boehringer Mannheim, Mannheim,
Germany). Detection was performed using enhanced chemilumi-
nescence (Amersham, Oakville, Ontario, Canada) and XAR
x-ray film (Kodak). Results were quantitated by image analysis,
and statistical significance was determined using Student’s t test.
For biochemical analysis of BDNF, brain lysates were boiled in
sample buffer, and 20–100 mg of protein was separated on a 15%
SDS-polyacrylamide minigel, as described previously (Causing et
al., 1997; Fawcett et al., 1997). After transfer, the nitrocellulose
was blotted with an antibody specific to BDNF (Santa Cruz) at a
1:5000 dilution, using the protocols described above. As controls,
we used human recombinant BDNF (obtained from Amgen,
Thousand Oaks, CA), and an extract of PC12 cells infected with
vaccinia virus encoding BDNF (Causing et al., 1997).
Immunocytochemistry. Two different BDNF antibodies were
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used for the immunocytochemical studies (the Santa Cruz anti-
body that was used for Western blots does not work for immu-
nocytochemistry). One, an anti-peptide antibody, was used for
detection of BDNF synthesis in the DBH–BDNF transgenic mice
and has previously been shown to work for immunocytochemistry
(Patterson et al., 1996) (W. Friedman and D. Kaplan, unpub-
lished data). A second, more sensitive BDNF antibody (RAB)
was used for the BDNF–DBH double-labeling studies. This an-
tibody has previously been characterized (Yan et al., 1997b) and
demonstrated to detect BDNF in nerve fibers and terminals
(Conner et al., 1997; Fawcett et al., 1997; Yan et al., 1997b) and
was the kind gift of Dr. A. Welcher (Amgen). A commercially
available antibody (EugeneTech) was used to detect DBH immu-
nocytochemically. For fluorescence immunocytochemical detec-
tion of BDNF and DBH in locus coeruleus neurons, 14-mm-thick
cryosections on slides were post-fixed with 4% paraformaldehyde
in 0.1 M phosphate buffer for 2 min at room temperature and
washed 2 3 10 min in 1 M HEPES-buffered saline (HBS), pH 7.4.
Sections were permeabilized with HBS plus 0.2% Triton X-100,
blocked with 3% serum for 45 min at room temperature, and
incubated with the primary antibody in HBS plus 0.2% Triton
X-100 plus 3% serum overnight at 4°C at a dilution of 1:500 for
anti-BDNF and 1:600 for anti-DBH. Slides were then washed 3 3
15 min in HBS. Binding of the primary antibody was visualized
with a rhodamine-conjugated secondary antibody (goat anti-
rabbit IgG at a 1:200 dilution; Jackson). Slides were then washed,
mounted with a 10% glycerol, 90% PBS solution, and cover-
slipped. In all cases, control and transgenic tissue were prepared
at the same time and analyzed on the same slides.
For immunoperoxidase detection of DBH, the primary anti-
body was used as above (1:600 dilution; Eugene Tech), with the
exception that DBH was visualized using a biotin-conjugated
secondary antibody (goat anti-rabbit dilution 1:200; Vector Lab-
oratories, Burlingame, CA), and PBS, pH 7.4, was used as a
buffer. Slides were then washed as before and incubated with the
ABC complex (Vector) for 1 hr at room temperature and then
with DAB for ;5 min, or until desired staining was reached. In all
cases, control and transgenic tissue were prepared at the same
time and analyzed on the same slides.
For the double-label analysis of BDNF and DBH, 10-mm-thick
sections were blocked in PB, pH 7.4, containing 10% normal goal
serum and 0.2% Triton X-100 for 1 hr. BDNF (Amgen) and DBH
antibodies were then added to the blocking solution at dilutions of
1:5000 and 1:1000, respectively, for 24 hr at 4°C. Sections were
washed three times in the blocking solution and then incubated
for 1 hr in blocking solution containing an anti-rabbit CY3-
conjugated antibody to detect anti-BDNF and an anti-mouse
CY2-conjugated antibody to detect anti-DBH, both used at a
dilution of 1:1000. Sections were then washed in PBS and
mounted in 50% glycerol in PBS containing 2% Dabco. Sections
were analyzed and photographed on a Zeiss Axioscope, using
filters that were designed for double-label analysis using these two
fluorochromes.
Quantitation of the relative level of immunoreactivity for
BDNF in locus coeruleus neurons from DBH–BDNF versus
control animals was performed using image analysis. Five differ-
ent pairs of line D481 versus control animals were analyzed.
Specifically, transgenic and control neurons were analyzed by
immunofluorescence at the same time (and in many cases, on the
same slide) and were photographed using the same exposure and
developing times. These photographic images were scanned, and
the relative fluorescence intensity was measured and expressed as
mean optical density per neuron. The background level of fluo-
rescence, measured lateral to the locus coeruleus neuron cluster,
was subtracted from the values obtained for BDNF-positive cells.
Statistical significance was determined using Student’s t test.
Measurement of tissue monoamines. Animals were decapitated
swiftly with a guillotine, and their brains were removed quickly
and frozen at 280°C. The brains were later placed on a cold plate
to thaw, and a series of 1.0- to 1.5-mm-thick sections (usually four
to five) were cut. The brains from six wild-type and six transgenic
mice were dissected over the cold plate under microscopic obser-
vation, as described previously (Reader and Grondin, 1987;
Reader et al., 1989), and the following eight regions were taken
for the monoamine assays: frontal and entorhinal-piriform corti-
ces, neostriatum (caudate-putamen), thalamus, hypothalamus,
hippocampus, cerebellum, and brainstem. The discrete tissue
samples (10–20 mg wet weight) were placed in tubes already
containing 1–2 ml of 0.1N cold monochloroacetic acid with 2.15
mM Na2EDTA and disrupted in a glass homogenizer with a
Teflon pestle, and the homogenate was centrifuged at 39,000 3 g
for 45 min at 4°C. The pellets were dissolved overnight in 0.5 ml
of 1N NaOH for protein determinations (Lowry et al., 1951), and
the supernatants were assayed by HPLC with electrochemical
detection, following well established procedures (Lakhdar-
Ghazal et al., 1986; Sauve and Reader, 1988). Briefly, the super-
natants were filtered through 0.45 mm pores (GS; Millipore,
Bedford, MA) and injected into the 3-mm-particle-size chromato-
graphic column (100.0 3 4.1 mm) (Adsorbosphere Catechol-
amine; Alltech Associates, Deerfield, IL). The isocratic mobile
phase was 0.1N monochloroacetic acid adjusted to pH 3.3 with 1N
NaOH and containing 800 mg/l of Na2EDTA, 300 mg of sodium
octyl sulfate, and 10% of HPLC-grade methanol. The flow was
set at 0.6 ml/min, the temperature of the column was kept at 37°C,
and the electrochemical detector (Model M-400; Princeton Ap-
plied Research, Princeton, NJ) was set at a gain of 50 nA full
scale for neostriatum and brainstem and at 20 nA full scale for the
remaining regions. The eluted compounds were oxidized with a
glassy carbon electrode at a potential of 0.68 V relative to the
Ag/AgCl reference electrode. The peaks generated by the com-
pounds were recorded, and their surfaces were integrated with a
Hewlett Packard 3392A integrator. For every chromatographic
run, external standards containing 1.25 ng of each of the authentic
monoamines were injected to quantify peak area as well as
retention times. Both parameters showed very good reproducibil-
ity, with a coefficient of variation never exceeding 5%. Although
the method allows for the separation of catecholamines, in-
doleamines, and their major metabolites (Reader and Grondin,
1987), only the tissue levels of noradrenaline (NA), dopamine
(DA), 3,4-dihyroxyphenylacetic acid (DOPAC), homovanillic
acid (HVA), 3-methyoxytyramine (3-MT), serotonin (5-HT), and
5-hydroxyindole-3-acetic acid (5-HIAA) are reported here, in
nanograms per milligram of protein.
RESULTS
BDNF and dopamine-b-hydroxylase are partially
colocalized in fibers and nerve terminals in the
adult brain
To determine whether BDNF, which is synthesized by central
noradrenergic neurons (Castren et al., 1995; Conner et al., 1997),
is anterogradely transported into noradrenergic axons and nerve
terminals, we performed double-label immunocytochemical anal-
ysis for BDNF and dopamine-b-hydroxylase (DBH), a marker for
noradrenergic and adrenergic neurons and fibers (Figs. 1, 2),
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Figure 1. Colocalization of BDNF and dopamine-b-hydroxylase (DBH ) in fibers and nerve terminals in the adult rat brain. Fluorescence photomi-
crographs of the rat brainstem double-labeled with antibodies to BDNF (A, D, visualized using a CY3-labeled secondary antibody) and DBH (B, E,
visualized using a CY2-labeled secondary antibody). C and F are photographic double exposures; in these panels, yellow indicates regions of double
labeling. A–C, The region of noradrenergic innervation rostral to the ventrolateral reticular region. Noradrenergic neuron cell bodies are DBH-positive
(asterisk) but are largely negative for BDNF, with some cells exhibiting faint BDNF immunoreactivity (large arrowhead). However, the processes of these
noradrenergic neurons are largely positive for both BDNF and DBH (arrows). D–F, The ventrolateral periolivary region is immunoreactive for both the
BDNF (D) and DBH antibody (E), with punctate staining that may represent terminals or cut fibers. Space bar, 50 mm.
Figure 2. BDNF and DBH are colocalized in axons in the brainstem. Fluorescence photomicrographs of brainstem sections double-labeled for BDNF
and DBH as described in Figure 1. A–C, BDNF and DBH are colocalized in fine processes in the rostral ventrolateral reticular region (arrows). D–F,
BDNF and DBH are colocalized in fibers (arrows) in the ventrolateral periolivary region. The occasional single double-labeled punctate structure can
be visualized in this region (arrowhead). Space bars, 25 mm.
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using a specific BDNF antibody (RAB) from Amgen that has
been characterized previously (Conner et al., 1997; Fawcett et al.,
1997; Yan et al., 1997b) and a commercially available monoclonal
(DBH) antibody. We chose to focus on the brainstem for these
studies, because both BDNF- and DBH-positive fibers are
abundant in this brain region (Moore and Card, 1984; Conner
et al., 1997).
This analysis revealed that although many DBH-positive fibers
were not immunoreactive for BDNF and many BDNF-positive
fibers were not immunoreactive for DBH, these two proteins were
highly colocalized in certain brainstem structures (Fig. 1). As
reported previously (Conner et al., 1997), noradrenergic neuron
cell bodies were largely negative for BDNF immunoreactivity,
although faint immunostaining could be seen occasionally in the
soma of DBH-positive noradrenergic neurons (Fig. 1A–C). How-
ever, BDNF immunoreactivity was detected in the network of
DBH-positive processes that surround noradrenergic cell groups,
such as those of the ventrolateral reticular group (Fig. 1A–C). In
these locations, DBH-positive fibers were also BDNF-positive,
and in some cases BDNF immunoreactivity was detected in
DBH-positive processes as they exited the noradrenergic cell
soma (Fig. 1A–C). At higher magnification, this colocalization
could be seen to occur in single noradrenergic fibers (Fig. 2A–C).
These data, together with previous in situ hybridization data
(Castren et al., 1995), indicate that BDNF is synthesized by
noradrenergic neurons and is transported from the cell soma into
noradrenergic processes.
BDNF was also colocalized to DBH-positive fibers rostral and
lateral to noradrenergic cell groups. In particular, BDNF was
colocalized with DBH-positive fibers, presumably axons, in the
rostroventrolateral periolivary region (Figs. 1D–F). Higher-
resolution analysis (Fig. 2D–F) revealed that in some cases, this
colocalization occurred in fibers coursing through the tissue sec-
tion (Fig. 2D–F), whereas in others the colocalized immunore-
activity was punctate in nature, reflecting either noradrenergic
terminals or axons cut in cross-section (Fig. 2D–F, arrowheads).
Both DBH and BDNF terminal staining was also seen in the
raphi pallidus, a terminal field of noradrenergic innervation (data
not shown). Thus, BDNF can be immunocytochemically detected
in noradrenergic axons and nerve terminals.
DBH–BDNF mice overexpress BDNF in central
noradrenergic neurons
These data indicate that BDNF is anterogradely transported by
noradrenergic afferents, and they suggest that it may be secreted
from noradrenergic terminals, thereby regulating the develop-
ment and maintenance of their target neurons. To test this
hypothesis, we took advantage of transgenic mice that overex-
press BDNF in noradrenergic neurons from the dopamine-b-
hydroxylase promoter (DBH–BDNF mice) (Causing et al.,1997).
We have demonstrated previously that in two lines of DBH–
BDNF mice, D498 and D481, BDNF synthesis is increased
approximately two- to fourfold in sympathetic noradrenergic
neurons, with no ectopic expression or secretion of BDNF into
the circulation. To determine whether BDNF is also overex-
pressed in central noradrenergic neurons, as predicted (Hoyle et
al., 1994), we examined the locus coeruleus. Immunocytochemical
analysis using a BDNF-specific antibody (Patterson et al., 1996)
(W. Friedman and D. Kaplan, unpublished data) demonstrated
BDNF-immunoreactivity detectable in a few neuronal cell bodies
within the control locus coeruleus (Fig. 3A). In contrast, BDNF
immunoreactivity was evident in most locus coeruleus neuron
bodies in DBH–BDNF animals from lines D481 (Fig. 3B) and
D498 (data not shown). Image analysis of the fluorescence inten-
sity per locus coeruleus neuron revealed that BDNF immunore-
activity was reproducibly increased in four different pairs of
control versus line D481 DBH–BDNF animals (5.52 6 0.29 vs
11.19 6 0.38, n 5 52 and 78, p , 0.0001; 11.27 6 0.57 vs 16.09 6
0.72, n 5 41 and 90, p , 0.0001; 9.57 6 0.35 vs 17.04 6 0.87, n 5
141 and 71, p , 0.0001; 9.88 6 1.78 vs 21.57 6 1.61, n 5 15 and
43, p , 0.0002; in all four pairs, the data represents the mean
fluorescence intensity 6 the SE, and n represents the number of
neurons analyzed). Thus, the DBH–BDNF transgene was ex-
pressed in both central and peripheral (Causing et al., 1997)
noradrenergic neurons.
To confirm this conclusion, we also quantitated BDNF in the
brains of control versus DBH–BDNF mice by Western blot anal-
ysis. We initially examined the brains of 1-week-old mice, after
the onset of expression from the dopamine-b-hydroxylase pro-
moter (Kapur et al., 1991), at a time when endogenous BDNF
levels are low (Maisonpierre et al., 1990). Analysis of Western
blots revealed that brainstem BDNF levels increased ;1.8-fold
(n 5 5 each; p , 0.003) in 1-week-old transgenic animals of line
D498 relative to their control littermates (Fig. 4C, top). BDNF
levels similarly increased ;2.4-fold (n 5 5 each; p , 0.0007) in
the brainstem of adult animals of line D498 (Fig. 4C, bottom) and
D481 (data not shown). In contrast, BDNF levels were unchanged
in the cortex of adult line D481 animals (data not shown) or in the
neonatal or adult cortex of line D498 DBH–BDNF mice (n 5 5
each; p . 0.05) (Fig. 4A,B, bottom), as reported previously in the
spinal cord (Causing et al., 1997). Both the cortex and spinal
cord are locations in which there are no resident noradrenergic
or adrenergic neurons. Together with our previous findings
(Causing et al., 1997), this analysis indicates that BDNF synthesis
is increased in developing and mature noradrenergic neurons of
DBH–BDNF mice and that this overexpression is confined to
regions of the nervous system predicted by previous analysis of
the 1.6 kb DBH promoter (Hoyle et al., 1994).
Increased BDNF synthesis by noradrenergic neurons
anterogradely regulates cortical development
If BDNF synthesized by noradrenergic neurons is anterogradely
transported and secreted onto target neurons, then we would
predict, in the DBH–BDNF mice, an increase in the baseline
level of TrkB autophosphorylation in targets such as the neocor-
tex. To test this prediction, we isolated cortical tissue from neo-
natal and adult mice, immunoprecipitated the lysates with anti-
panTrk 203, and then analyzed the immunoprecipitates by
Western blot analysis with antiphosphotyrosine. We reprobed the
blots for total TrkB receptor levels using anti-TrkBout and nor-
malized the level of increase in Trk autophosphorylation relative
to total TrkB levels. This analysis indicated that levels of auto-
phosphorylation of a 145 kDa Trk band were specifically in-
creased 2.8-fold (n 5 8 each; p , 0.003) in the cortex of 1-week-
old DBH–BDNF versus control animals (Fig. 4B, top), although
cortical BDNF levels were unchanged (Fig. 4B, bottom). Simi-
larly, in the adult DBH–BDNF cortex, the level of autophosphor-
ylation of the 145 kDa Trk band was increased ;2.5-fold relative
to controls (n 5 8 each; p , 0.05) (Fig. 4A, top). In the neonatal
cortex, the increased Trk autophosphorylation was limited to this
145 kDa Trk band (Fig. 4B), whereas in adult animals, we also
observed increased autophosphorylation of a 190 kDa Trk-
immunoreactive band (Fig. 4A). This phosphorylated Trk band
likely corresponds to a novel, 190 kDa TrkB that has been
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Figure 3. A, B, BDNF expression is increased in the locus coeruleus of DBH–BDNF mice. Fluorescence photomicrographs at the level of the locus
coeruleus in control (A) and line D481 DBH–BDNF (B) animals that were immunostained with an antibody specific to BDNF. Note that in control locus
coeruleus, the level of immunostaining is not above background, whereas in the DBH–BDNF locus coeruleus, there are many BDNF-immunoreactive
cell bodies (arrows). C–F, The level and pattern of dopamine-b-hydroxylase immunostaining is not altered in DBH–BDNF mice. C, D, Fluorescence
micrographs at the level of the locus coeruleus in control ( C) and line D481 DBH–BDNF ( D) animals that were immunostained with an antibody specific
to dopamine-b-hydroxylase, which recognizes noradrenergic and adrenergic neurons and fibers. The pattern and level of DBH immunostaining are
similar in both cases. E, F, Dark-field micrographs of coronal sections of the hippocampus from control (E) and line D481 DBH–BDNF (F) brains that
have been immunostained with anti-DBH and visualized with peroxidase. Both photographs derive from a similar level of the hippocampus, and the
dentate granule cell (DGc) and pyramidal cell (Py) layers are marked. Note that in dark field the DBH-positive nerve fibers appear bright silver–yellow
(arrows), and there are no apparent differences in the pattern or density of DBH-immunoreactive fibers in transgenic versus control animals. Scale bar,
100 mm.
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reported previously in both the PNS (Bhattacharyya et al., 1997)
and CNS (Roback et al., 1995) (R. Aloyz, D. Kaplan, and F. D.
Miller, unpublished observations). Thus, increased BDNF ex-
pression within brainstem noradrenergic neurons led to increased
Trk receptor autophosphorylation in the neocortex, a noradren-
ergic target region.
To determine whether the observed increase in TrkB receptor
activation in the neocortex modified cortical development and
maintenance, coronal sections of control versus DBH–BDNF
brains were stained with cresyl violet, and the gross morphology
of the neocortex was compared. Comparisons were made at two
levels as shown in Figure 5A. At the anterior level, the depth of
the cortex from the corpus callosum to the pia was consistently
smaller in animals of line D498 than in controls (Fig. 5B, top
panels). In contrast, cortical depth was similar in controls versus
DBH–BDNF mice at the more posterior level (Fig. 5B, bottom
panels). This observation was quantitated by determining the
number of neurons in 528-mm-wide strips of cortex in control
versus transgenic animals. At the anterior level, there were
2269.0 6 41.45 cells per 528-mm-wide strip of transgenic cortex,
compared with 2505 6 21.55 in controls, a statistically significant
decrease of 10% ( p , 0.002; n 5 5 each). At the posterior level,
Figure 4. A, B, Endogenous levels of TrkB autophosphorylation are increased in the cortex of DBH–BDNF mice, whereas BDNF levels are unchanged.
Top, Cortical lysates from individual adult (A) and 1-week-old ( B) control (2) and line D498 DBH–BDNF (1) animals were immunoprecipitated with
anti-panTrk, and then analyzed by Western blots with antiphosphotyrosine (4G10). To ensure that the observed increases reflected an increase in the
activation of TrkB, the blots were reprobed with anti-TrkBout (TrkB). Image analysis quantitation was used to normalize the level of autophosphorylation
of the 145 kDa TrkB band relative to levels of TrkB protein. The normalized data (shown in the graphs, with an n of at least 3 individual animals in
each case) were analyzed statistically for significance using a Student’s t test. *p , 0.05; **p , 0.005. The size of the two TrkB isoforms is indicated by
145 and 190. Bottom, Western blot analysis of BDNF protein in the cortex of individual adult (A) and 1-week-old (B) control (2) and line D498
DBH–BDNF (1) mice. The graphs represent image analysis quantification of the data obtained on the same Western blot of three individual control
and transgenic animals, with the optical density (O. D.) being arbitrary numbers. C, BDNF levels are increased in the brainstem of DBH–BDNF mice.
Western blot analysis of BDNF protein in the brainstem of individual 1-week-old (top) and adult (bottom) control (2) versus line D498 DBH–BDNF
(1) mice. The graphs represent image analysis quantification of the data obtained on the same Western blot of three individual control and transgenic
animals, with the optical density (O. D.) being arbitrary numbers. Statistical analysis of these data demonstrates that BDNF is significantly increased in
the brainstem of adult and neonatal DBH–BDNF animals. *p , 0.05; **p , 0.005.
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Figure 5. Overexpression of BDNF in noradrenergic neurons leads to decreased neuronal numbers in the anterior neocortex. A, Schematic drawing
showing the rostral and caudal levels that were analyzed for morphology of the neocortex. B, Photomicrographs of coronal Nissl-stained sections of the
neocortex of control and DBH–BDNF transgenic mice. Rightmost and lef tmost panels are from control animals, whereas the three innermost panels are
all from line D498 DBH–BDNF animals. The top set represents the rostral level of the neocortex indicated in A, and the bottom set represents the caudal
level. Brackets define approximate boundaries of the different cortical layers indicated in the lef tmost panel. Scale bar, 70 mm.
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there were 1860.38 6 54.44 cells in DBH–BDNF mice, compared
with 1953.7 6 68.1 cells in control mice, numbers that were
statistically similar ( p . 0.05); n 5 5 each). Consistent with these
observations, noradrenergic innervation is most dense in the
rostral neocortex (Schlumpf et al., 1980). Thus, increased antero-
grade secretion of BDNF from noradrenergic neurons affects
cortical development and maintenance, most probably through
activation of endogenous TrkB receptors.
Increased synthesis of BDNF by noradrenergic
neurons rescues neonatal facial motoneurons from
axotomy-induced death
Our cortical results support the hypothesis that anterogradely
secreted BDNF regulates the development and maintenance of
noradrenergic target neurons. To further test this hypothesis, we
turned to neonatal facial motoneurons because (1) motoneurons
receive noradrenergic innervation (Pickel et al., 1974; McBride
and Sutin, 1976) and (2) neonatal facial motoneurons, which
normally die in response to facial nerve axotomy, can be rescued
by application of exogenous BDNF (Koliatsos et al., 1993;
Sendtner et al., 1993). We predicted that neonatal facial motoneu-
rons would be rescued from axotomy-induced death in DBH–
BDNF mice because of increased BDNF supplied by their nor-
adrenergic input.
To perform these experiments, we initially characterized facial
motoneuron size and number in DBH–BDNF mice. Image anal-
ysis of serial, cresyl violet-stained coronal sections from the brain-
stem of P12 control versus DBH–BDNF mice revealed that facial
neuron numbers were unchanged by expression of BDNF in
noradrenergic neurons (control, 2987 6 514; D481, 3248 6 200;
D498, 2838 6 471; n 5 3 animals each; p . 0.3 for all compari-
sons). In contrast, the average cross-sectional area of facial mo-
toneurons was increased ;35 and 25%, respectively, in lines
D481 and D498 relative to control animals (Fig. 6A) (control,
256.8 6 9.2 mm2; D481, 384.8 6 8.5 mm2; D498, 333.8 6 15.4
mm2; n 5 4 animals each for D498 and control and 3 for D481;
p , 0.002 for both comparisons).
We next determined whether increased BDNF from noradren-
ergic neurons could rescue the death of axotomized, neonatal
facial motoneurons, as can exogenous BDNF (Koliatsos et al.,
1993; Sendtner et al., 1993). For these experiments, the facial
nerve was unilaterally transected at postnatal day 5, and 1 week
later the number of facial motoneurons in the contralateral con-
Figure 6. A, Facial motorneurons are
hypertrophied in neonatal DBH–BDNF
transgenic mice. The average cross-
sectional area of P12 facial motoneurons
was determined by image analysis of
cresyl violet-stained coronal sections of
the appropriate brainstem level of DBH–
BDNF mice of lines D498 and D481
versus their control littermates. In both
lines of DBH–BDNF mice, facial mo-
toneurons were significantly hypertro-
phied. ***p , 0.005. B, Neonatal facial
motoneurons are rescued from axotomy-
induced death in DBH–BDNF trans-
genic animals. The facial nerves of 5-d-
old control and DBH–BDNF animals
were unilaterally transected, and 7 d
later, serial 16 mm sections were col-
lected throughout the entirety of the fa-
cial nuclei. The number of facial mo-
toneurons was then determined in the
contralateral, control versus ipsilateral,
transected facial nuclei by image analysis
quantification of the number of facial
motoneurons in every fifth section. The
results of this analysis are presented as a
ratio of the number of neurons in the
transected versus untransected nuclei.
The mean number of facial motoneurons
within each group is presented within
the text. Note that in control littermates,
only 28% of facial motoneurons remain 1
week after a facial nerve transection,
whereas in lines D498 and D481, 69 and
66% of facial motoneurons remain, re-
spectively. ***p , 0.005; n 5 at least
three animals in each group. C, Survival
of transected facial motoneurons is re-
duced in adult BDNF1/2 mice com-
pared with their BDNF1/1 littermates.
Methods similar to those described in B
were used, with the exception that uni-
lateral facial nerve transections were performed on 3-month-old BDNF1/2 versus BDNF1/1 animals. The results of this analysis are presented as a
ratio of the number of neurons in the transected versus untransected nuclei. Note that in BDNF1/1 littermates, 87% of motoneurons remain 1 week
after a facial nerve transection, whereas in BDNF1/2 mice, only 71% of facial motoneurons remain. ***p , 0.05; n 5 3 animals in each group. D, BDNF
levels are decreased in the BDNF1/2 brain. Western blots of equal amounts of protein from the cortex of BDNF1/2 versus BDNF1/1 mice were
probed with an antibody to BDNF. A similar decrease was observed in other regions of the BDNF1/2 brain (data not shown).
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trol versus ipsilateral transected facial nuclei was determined.
Specifically, serial 16 mm coronal sections were collected through-
out the entirety of the facial motor nuclei, and the number of
motoneurons was determined in every fifth cresyl violet-stained
section (Fig. 6B). In control littermates, only 28% of axotomized
neonatal facial motoneurons survived relative to their uninjured
counterparts (control uninjured neuron number, 2579 6 546;
control axotomized neuron number, 631 6 75; n 5 4 each). In
contrast, in animals of lines D481 and D498, 66 and 69% of facial
motoneurons, respectively, remained in the axotomized versus
uninjured facial nuclei (line D481 uninjured neuron number,
3248 6 200; line D481 injured neuron number, 2133 6 159; line
D498 uninjured neuron number, 2521 6 460; line D498 injured
neuron number, 1721 6 277; n 5 3 for D481 and n 5 4 for D498).
This increase in facial motoneuron survival in the DBH–BDNF
mice was highly significant relative to control animals ( p , 0.006
for D498; p , 0.009 for D481) and is similar to the level of rescue
reported previously for exogenous BDNF (Koliatsos et al., 1993;
Sendtner et al., 1993).
Decreased synthesis of BDNF in BDNF1/2 mice leads
to increased death of axotomized adult
facial motoneurons
Our data indicate that alterations in BDNF levels directly regu-
late the survival of injured motoneurons. To test this hypothesis
further, we examined BDNF1/2 mice, in which one BDNF
allele has been mutated by targeted recombination. To confirm
that BDNF levels are decreased in the brains of BDNF1/2 mice
relative to controls, we quantitated BDNF by Western blot anal-
ysis. This analysis revealed that BDNF levels were decreased
approximately twofold in regions throughout the adult
BDNF1/2 brain (Fig. 6D), as reported previously using ELISAs
(Altar et al., 1997). To determine whether this decrease in en-
dogenous BDNF levels affected the survival of injured motoneu-
rons, the facial nerve was unilaterally transected in adult
BDNF1/2 mice or their BDNF1/1 littermates, and 1 week later
the number of surviving facial motoneurons was determined by
morphological analysis (Fig. 6C). This analysis revealed that in
BDNF1/1 littermates, 87 6 1.6% of transected facial motoneu-
rons remained relative to the control, untransected motoneurons,
as observed previously in control mice (Majdan et al., 1997). In
contrast, in BDNF1/2 mice, only 71 6 4% of transected facial
motoneurons remained, relative to the untransected facial mo-
toneurons in the same animals (Fig. 6C), a statistically significant
decrease of 18% ( p , 0.05; n 5 3 animals each). These results,
together with those obtained from the DBH–BDNF mice, sup-
port the hypothesis that the survival of injured facial motoneu-
rons is at least partially dependent on BDNF and that relatively
small alterations in BDNF levels can tightly regulate the survival
of injured BDNF-responsive neurons.
Noradrenergic innervation is not altered in
DBH–BDNF mice
Although our results indicate that anterogradely transported
BDNF regulates neuronal development and maintenance by ac-
tivation of the TrkB receptor, noradrenaline has been previously
proposed to have trophic effects (Maeda et al., 1974; Felten et al.,
1982; Foote et al., 1983), and it is formally possible that some of
the observed biological effects in the DBH–BDNF mice are
attributable to increased catecholaminergic innervation. To ex-
amine this possibility, we examined morphological and neuro-
chemical measures of noradrenergic innervation density. Initially,
we compared the level of immunostaining for dopamine-b-
hydroxylase, which is specific to noradrenergic and adrenergic
neurons, in the brains of control versus DBH–BDNF mice (Fig.
3C–F). As predicted, anti-DBH robustly stained the noradrener-
gic neurons of the locus coeruleus, with no significant qualitative
different between control (Fig. 3C) and D481 (Fig. 3D) or D498
(data not shown) animals. To determine whether the level of
noradrenergic target innervation was altered, we examined the
hippocampus, which has a well defined pattern of noradrenergic
innervation (Swanson and Hartman, 1975; Loy et al., 1980;
Moudy et al., 1993). In control (Fig. 3E), D481 (Fig. 3F), and
D498 (data not shown) animals, the pattern and density of DBH-
positive innervation was similar. Thus, the pattern of noradrener-
gic innervation was not apparently altered in DBH–BDNF mice.
To assess quantitatively catecholaminergic innervation, tissue
levels were measured in discrete CNS regions, using HPLC with
electrochemical detection. This method allowed for the measure-
ment of noradrenaline (NA) and dopamine (DA), of the major
metabolites of DA, namely DOPAC, HVA, and 3-MT, as well as
of the indoleamines serotonin (5-HT) and 5-HIAA (Tables 1, 2).
In all regions examined, the levels of noradrenaline were similar
in control versus transgenic animals ( p . 0.05), confirming that
noradrenergic innervation was not altered in these animals. In
frontal cortex (Fro) the main catecholamine was NA, and al-
though levels of this catecholamine were unaltered, this was the
only CNS region in which endogenous DA levels were found to be
somewhat higher in transgenic mice (Table 1). The entorhinal-
piriform (EnPi) cortex had similar levels of NA and DA, as
expected, and there were no differences detected. In hippocampus
(Hipp), DA and its metabolites were not detected in the majority
of samples; the main catecholamine was NA, which was unal-
tered. The main catecholamine in the neostriatum (NS; caudate-
putamen) was DA, and there were also high levels of its metab-
olites DOPAC, HVA, and 3-MT; this was the only region in
which significant levels of 3-MT were detected and measured in
all samples. The indoleamines 5-HT and 5-HIAA were present
in all of these regions, with values ranging from 3 to 5 ng/mg of
protein, but there were no significant differences between control
and transgenic mice, suggesting a normal 5-HT innervation of
these forebrain areas. In the thalamus (Thal) of both control and
transgenic mice there were moderate levels of NA, but also of DA
and its metabolites DOPAC and HVA (Table 2), and somewhat
higher (5–7 ng/mg of protein) levels of 5-HT and 5-HIAA.
Interestingly, in the hypothalamus (Hypo) the tissue levels of DA
were lower in the transgenic mice relative to controls. Despite this
reduction in endogenous DA, the levels of its metabolites
DOPAC and HVA were unchanged, suggesting an increased
turnover rate. The levels of the indoleamines 5-HT and 5-HIAA
were similar in control and transgenic mice. In the brainstem the
high contents of NA (4–5 ng/mg of protein), 5-HT (8 ng/mg of
protein), and 5-HIAA (8–9 ng/mg of protein) reflect the fact that
this region contains the nuclei of origin of noradrenergic and
serotonergic projections. There were no differences between con-
trol and transgenic mice in levels of NA, DA, DOPAC, HVA, or
the indoleamines in this region. Finally, in the cerebellum only
moderate to low levels of NA, 5-HT, and 5-HIAA were mea-
sured, and the tissue contents were the same in control and
transgenic mice.
DISCUSSION
Evidence indicates that neuronal survival and differentiation is
dependent on the appropriate establishment of afferent inputs
(for review, see Linden, 1994). In this paper, we have tested the
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hypothesis that BDNF functions as an anterograde trophic factor
for central noradrenergic neurons. The results reported here
support our hypothesis and lead to three major conclusions. First,
our data indicate that BDNF is synthesized by noradrenergic
neurons and is anterogradely transported into noradrenergic ax-
ons and nerve terminal fields. Second, we demonstrate that over-
expression of BDNF in noradrenergic neurons of DBH–BDNF
mice has measurable anterograde effects on the cortex, leading to
increased activation of cortical TrkB receptors, and differences in
cortical morphology. Third, our studies demonstrating rescue of
axotomized neonatal facial motoneurons in DBH–BDNF mice
indicate that increased BDNF from noradrenergic afferents can
directly regulate neuronal survival. Together, these data indicate
that anterogradely secreted BDNF can modulate neuronal sur-
vival and differentiation and suggest that the effects of noradren-
ergic afferents on target neuron development may be at least
partially mediated by BDNF.
Previous studies have demonstrated that BDNF is present in
axons and nerve terminals in the mature CNS (Conner et al.,
1997; Fawcett et al., 1997), and that TrkB, the preferred
receptor for BDNF, is present on the dendrites of many central
neurons (Fryer et al., 1996). Together, these data led us to
hypothesize that BDNF might be an anterograde neurotrophic
factor within the CNS and that it might mediate some of the
previously described effects of afferent innervation on target
neuron development. To test this hypothesis, we focused on
central noradrenergic neurons, which synthesize BDNF
mRNA (Castren et al., 1995) and have long been thought to
play an organizational role in development of targets such as
the neocortex (Maeda et al., 1974; Felten et al., 1982). The
double-labeling data presented here indicate that BDNF may
well be an anterograde trophic factor for these neurons; BDNF
is localized to processes of noradrenergic neurons as they exit
the cell soma, in noradrenergic axons in regions lateral to the
cells themselves, and in noradrenergic terminal fields. These
colocalization data, together with previous studies demonstrat-
Table 2. Monoamines and metabolites in thalamus (Thal), hypothalamus (Hypo), brainstem (BS), and cerebellum (CB) of control and transgenic
mice
Compound Thal Hypo BS CB
NA Control 3.74 6 0.80 13.03 6 1.35 5.51 6 1.08 1.38 6 0.18
Transgenic 3.56 6 0.70 8.15 6 1.76 4.69 6 0.77 1.10 6 0.45
DA Control 2.30 6 0.74 2.13 6 0.45 1.05 6 0.18 n.d.
Transgenic 1.73 6 0.61 0.99 6 0.11* 0.96 6 0.21 n.d.
DOPAC Control 2.23 6 0.54 6.72 6 0.53 0.99 6 0.16 n.d.
Transgenic 2.89 6 0.75 6.39 6 1.64 0.86 6 0.17 n.d.
HVA Control 2.50 6 0.75 2.82 6 1.11 1.01 6 0.18 n.d.
Transgenic 3.40 6 2.51 3.23 6 0.72 1.23 6 0.27 n.d.
5-HT Control 5.08 6 0.63 6.61 6 1.33 7.97 6 1.09 1.83 6 0.43
Transgenic 5.85 6 1.03 7.76 6 1.98 8.42 6 0.97 1.89 6 0.55
5-HIAA Control 7.61 6 0.42 8.12 6 1.66 9.48 6 1.20 1.59 6 0.28
Transgenic 6.99 6 1.25 7.37 6 1.41 8.64 6 1.31 1.95 6 0.27
The values are the means 6 SEM (n 5 6) in nanograms per milligram of protein. The compounds are NA, noradrenaline; DA, dopamine; DOPAC, 3,4-dihydroxypheny-
lalanine; HVA, homovanillic acid; 5-HT, serotonin; and 5-HIAA, 5-hydroxyindole-3-acetic acid. n.d., Not determined. Statistical comparisons were made by Student’s t test.
*p , 0.05.
Table 1. Monoamines and metabolites in frontal (Fro) and entorhinal-piriform (EnPi) cortices, hippocampus (Hipp), and neostriatum (NS) of
control and transgenic mice
Compound Fro EnPi Hipp NS
NA Control 1.12 6 0.16 0.90 6 0.23 2.85 6 0.91 4.77 6 0.92
Transgenic 1.72 6 0.31 0.91 6 0.18 3.63 6 0.72 3.46 6 0.94
DA Control 0.16 6 0.05 1.16 6 0.40 n.d. 58.26 6 3.13
Transgenic 0.34 6 0.06* 0.77 6 0.16 n.d. 64.50 6 9.29
DOPAC Control 0.22 6 0.05 0.75 6 0.34 n.d. 19.09 6 4.42
Transgenic 0.30 6 0.04 0.72 6 0.22 n.d. 16.72 6 2.51
HVA Control n.d. n.d. n.d. 5.13 6 0.98
Transgenic n.d. n.d. n.d. 5.74 6 1.02
3-MT Control n.d. n.d. n.d. 4.42 6 0.46
Transgenic n.d. n.d. n.d. 5.46 6 0.97
5-HT Control 4.02 6 1.31 5.25 6 1.18 4.75 6 1.18 3.25 6 0.74
Transgenic 4.71 6 0.69 4.53 6 1.65 7.03 6 1.57 3.73 6 0.74
5-HIAA Control 2.90 6 0.80 3.38 6 0.80 5.70 6 1.29 4.32 6 0.74
Transgenic 2.25 6 0.33 3.04 6 0.79 6.90 6 1.18 4.77 6 1.19
The values are the means 6 SEM (n 5 6) in nanograms per milligram of protein. The compounds are NA, noradrenaline; DA, dopamine; DOPAC, 3,4-dihydroxypheny-
lalanine; HVA, homovanillic acid; 3-MT, 3-methoxytyramine; 5-HT, serotonin; and 5-HIAA, 5-hydroxyindole-3-acetic acid. n.d., Not determined. Statistical comparisons
were made by Student’s t test.
*p , 0.05.
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ing synthesis of BDNF mRNA by noradrenergic neurons
(Castren et al., 1995; Conner et al., 1997), strongly support the
hypothesis that BDNF is a candidate anterograde neurotro-
phic factor for this class of neurons.
One noradrenergic target that might well be regulated by
BDNF secreted from noradrenergic afferents is the neocortex.
Previous studies indicate that a chemical lesion of developing
noradrenergic neurons perturbs cortical development (Maeda et
al., 1974; Felton et al., 1982), indicating a key regulatory role for
early arriving afferents. Moreover, both BDNF and NT-4 regu-
late cortical development. Specifically, exogenous application of
BDNF prevents the formation of ocular dominance columns
(Cabelli et al., 1995) and regulates pyramidal neuron dendritic
growth (McAllister et al., 1995), whereas exogenous NT-4 causes
neuronal heterotopias, possibly by causing excess neurons to
migrate into the developing marginal zone (Brunstrom et al.,
1997). Moreover, endogenous BDNF is necessary for differenti-
ation of cortical interneurons (Jones et al., 1994) and is thought to
play an autocrine/paracrine role in cortical neuron survival
(Ghosh et al., 1994). These effects presumably occur through
activation of TrkB, which is present at high levels during cortico-
genesis (Escandon et al., 1994; Knusel et al., 1994), and which is
expressed on cortical neurons throughout the developing and
mature cortex (Cabelli et al., 1995; Fryer et al., 1996; Yan et al.,
1997b).
Our studies with the DBH–BDNF mice support the hypothesis
that noradrenergic afferents are likely to provide one endogenous
source of BDNF for the developing cortex. Previous work dem-
onstrates that the 1.6 kb DBH promoter used in these studies is
highly specific for noradrenergic and adrenergic cells and is not
ectopically expressed (Hoyle et al., 1994). Our data support this
conclusion. The two lines of DBH–BDNF mice described here
express increased BDNF in sympathetic neurons of the SCG and
in noradrenergic neurons of the locus coeruleus, with no apparent
increase in BDNF in the spinal cord or cortex (Causing et al.,
1997; data shown here). Moreover, the effects described here
cannot be ascribed to increased systemic BDNF, because (1)
BDNF is undetectable in the circulation of these animals
(Causing et al., 1997) and (2) sensory neurons of the dorsal root
ganglia, which hypertrophy in response to BDNF, are unaffected
in DBH–BDNF mice (C. Causing and F. Miller, unpublished
data). In addition, we have demonstrated that the pattern and
levels of noradrenergic innervation in the CNS (data shown here)
and PNS (Causing et al., 1997) of these mice are apparently
normal. Thus, the cortical effects we observe are best explained by
increased secretion of BDNF from noradrenergic and potentially
adrenergic afferents.
Interestingly, our data indicate that there is an increase in
cortical Trk autophosphorylation without an apparent increase in
cortical BDNF levels. The lack of a detectable increase in cortical
BDNF is relatively easy to explain; it is likely that the amount of
BDNF derived from noradrenergic afferents is small relative to
the total amount of BDNF in the cortex, and therefore even a
two- to fourfold increase in the amount of BDNF from this
source is masked by endogenous cortical BDNF. Why, then, is
there a two- to threefold increase in the basal level of Trk
autophosphorylation? We propose that much of the BDNF
present in cortical neurons and their afferents is packaged in
secretory vesicles (Fawcett et al., 1997) and is therefore unavail-
able to neuronal TrkB receptors until it is released by neuronal
activity, much like a neuropeptide. In contrast, although the
amount of BDNF delivered by noradrenergic afferents is low
relative to the total amount of BDNF in the cortex, it is likely that
this BDNF is being secreted routinely, because noradrenergic
neurons are constitutively active during waking hours (Harley,
1991). Thus, we propose that the amount of TrkB receptor
activation in any given region of the cortex is not only a function
of the amount of BDNF present in that region, but also of the
amount of BDNF secretion that occurs in response to neuronal
activity. Support for this model derives from our recent findings
that pharmacological activation of cortical afferent systems leads
to rapid and dramatic increases in cortical TrkB autophosphory-
lation, presumably as a consequence of activity-dependent BDNF
release (R. Aloyz, J. Fawcett, and F. D. Miller, unpublished data).
What are the cortical perturbations observed in the DBH–
BDNF mice in response to this increased TrkB receptor activa-
tion? In rats, noradrenergic neurons are born from E10 to E13
(Lauder and Bloom, 1974), and their afferents reach the devel-
oping cortex by E16 (Schlumpf et al., 1980), a time point when
cortical neurons are actively being born, migrating, and differen-
tiating (Altman and Bayer, 1990; Bayer and Altman, 1990). These
afferents project through and branch into the marginal zone
(Levitt and Moore, 1979), which is essential for the appropriate
formation of cortical layers (Caviness, 1982) and which is one
site of perturbed cortical development in response to NT-4
(Brunstrom et al., 1997). The DBH promoter is turned on in
central noradrenergic neurons shortly after they are born (Hoyle
et al., 1994), and our results confirm the neonatal expression of
the DBH–BDNF transgene. The resultant increase in cortical Trk
receptor activation throughout postnatal development presum-
ably causes the decrease in neuronal number observed in the
anterior DBH–BDNF cortex. This phenotype could result from
any number of underlying mechanisms, including premature neu-
rogenesis, inappropriate migration, and alterations in neuronal
survival; our data do not discriminate among these possibilities.
Although the cellular mechanisms underlying the cortical phe-
notype reported here are unclear, the facial motoneuron studies
indicate that afferent BDNF can directly regulate neuronal sur-
vival. Facial motoneurons in the DBH–BDNF mice are not
rescued from developmental death, likely because they develop
early relative to their noradrenergic innervation (Bayer and
Altman, 1994). However, in neonates, when we know the DBH–
BDNF transgene is on, increased BDNF from noradrenergic
neurons causes facial motoneuron hypertrophy and rescues these
neurons from axotomy-induced death. Whether endogenous af-
ferent BDNF plays a similar role is unclear. However, our data
with the BDNF1/2 mice demonstrate that endogenous BDNF is
essential for the survival of these injured neurons, although these
studies do not directly determine the source of this endogenous
BDNF. Moreover, these latter studies demonstrate that relatively
small alterations in endogenous BDNF (approximately twofold)
are sufficient to determine motoneuron survival after injury.
Thus, these two studies together strongly support the idea that
alterations in the amount of BDNF secreted from noradrenergic
afferents could play a role in regulating the survival of developing
or injured target neurons.
In summary, our immunocytochemical data indicate that
BDNF is present in the axons and terminals of at least some
noradrenergic neurons, and our studies with the DBH–BDNF
mice indicate that such an afferent source of BDNF can affect the
survival, differentiation, and maintenance of target neurons. We
suggest that the previously documented trophic effects of norad-
renergic afferents on cortical development are at least partially
mediated by BDNF. Moreover, we suggest that activity-
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dependent presynaptic neurotrophin secretion and subsequent
activation of postsynaptic Trk receptors may provide a cellular
mechanism for modulating neural circuitry during development
or in the mature nervous system or both.
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